Hansoh Pharmaceutical Group Company Limited has announced a significant licensing agreement with Regeneron Pharmaceuticals, Inc. The agreement grants Regeneron an exclusive worldwide license, excluding the Chinese Mainland, Hong Kong, and Macau, to develop, manufacture, and commercialize HS-20094, an investigational dual GLP-1/GIP receptor agonist. The licensure will see Hansoh receiving an upfront payment of $80 million, with the potential for up to $1.93 billion in milestone payments tied to the product's development, regulatory approval, and commercialization. Additionally, Hansoh will earn double-digit royalties from potential future product sales. HS-20094 has completed multiple Phase II trials with positive results and is currently undergoing a Phase III clinical trial in China. This collaboration marks a strategic advancement for both companies in the biotechnology sector.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。